New drug combo aims to halt artery plaque after heart attacks

NCT ID NCT07612774

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding evolocumab, a cholesterol-lowering drug, to standard care can slow or stop plaque buildup in heart arteries after a heart attack. About 233 adults aged 40-75 who recently had a heart attack or unstable angina will receive either evolocumab plus standard therapy or standard therapy alone. Researchers will use advanced CT scans at the start and after 52 weeks to measure changes in plaque volume and artery narrowing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Evolocumab
What this could lead to: If it works, this could show that adding evolocumab to standard therapy slows or stops plaque buildup in heart arteries, potentially reducing future heart attack risk.
What could go wrong: This is a single-center, open-label trial with 233 participants, so results may not apply broadly. The study is early-stage for this specific combination, and evolocumab can cause side effects like injection site reactions or muscle pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome coronary artery disorder hypercholesterolemia, autosomal dominant, 3

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY CORONARY ARTERY DISEASE

Contacts and locations

Locations

West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.